Learn more. Guardant360 has several different applications. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Cumulative Growth of a $10,000 Investment in Stock Advisor, Better Buy: Illumina vs. Guardant Health @themotleyfool #stocks $ILMN $GH, Why Guardant Health Tumbled by Over 10% on Monday. Liquid biopsies have the potential to improve clinical outcomes, lower healthcare costs, and enable biopharma companies to advance new therapies. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. CareDx beats Guardant Health on 8 of the 15 factors compared between the two stocks. Guardant Health IPO: 5 things to know about the startup that wants to detect cancer early ... New competitors could also emerge. Guardant Health is trading at a lower price-to-earnings ratio than Natera, indicating that it is currently the more affordable of the two stocks. This is a breakdown of current ratings and recommmendations for Guardant Health and Natera, as provided by MarketBeat.com. Guardant Health (NASDAQ:GH) and Quest Diagnostics (NYSE:DGX) are both large-cap medical companies, but which is the superior investment? The companies' financial situations are similar, but Illumina has a larger growth opportunity once the COVID-19 impact settles. Fundamental company data provided by Morningstar and Zacks Investment Research. Guardant Health has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. Click here to find out how this upcoming precious metal explorer is identifying these extremely rare deposits…. It maintains over 70% of the sequencing market and specializes in providing instruments and tools to a variety of customers such as academic institutions and government, pharmaceutical, and biotechnology companies across the world. Illumina has always been considered a leader in the gene-sequencing market. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 Comparatively, 3.1% of CareDx shares are held by company insiders. Comparatively, Natera has a beta of 1.6, indicating that its stock price is 60% more volatile than the S&P 500. Guardant Health Inc is a small-sized business with medium revenue, that is new in its industry. Export data to Excel for your own analysis. Management believes that there is an estimated market opportunity of over $50 billion in the U.S. Guardant currently offers two products, Guardant360 and GuardantOMNI, for advanced stage cancer. Laboratory Co. of America has higher revenue and earnings than Guardant Health. Guardant Health beats Invitae on 10 of the 14 factors compared between the two stocks. Veracyte is trading at a lower price-to-earnings ratio than Guardant Health, indicating that it is currently the more affordable of the two stocks. We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation. Veracyte has a consensus price target of $40.8333, suggesting a potential downside of 24.83%. Guardant Health has higher earnings, but lower revenue than Natera. Guardant Health has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. Data Sources: Yahoo Finance, Illumina, Guardant Health. The publication provides annual rankings and firm-by-firm editorial, including leading lawyers. Precision oncology company Guardant Health, buoyed by its Guardant360 assay for matching cancer patients with ⦠Future Competition: Guardant Health's Fastest Growing Competitors These companies are in the same general field as Guardant Health and are rapidly expanding. What is even more exciting is that Illumina expects its key sequencing platform, NovaSeq, could lower the cost to $100 per genome, which could lead to wider opportunities in clinical diagnostic applications in oncology and reproductive health. Impact of Covid 19 on the Tumor Testing market in 2020 in depth research on prices , stocks , volume and growth , latest news and results , expansion plan , current business strategy , key company , sales , revenue and competition , production and consumption , supply and demand , industry and business studies , impact of Covid 19 buyers and sellers and forecast for 2020 â 2025 Avient (NASDAQ:AVNT) Is A Buy But Wait For The Next Pullback, Airbnb (NASDAQ:ABNB) Suffers at Gordon Haskett, But Don't Count it Out, 8 EV Stocks To Electrify Your Growth Portfolio, 7 Cloud Computing Stocks to Lift Your Portfolio to New Heights, 7 Infrastructure Stocks That May Help Rebuild America, 7 Food Stocks That Are Leading Through Innovation, 7 Entertainment Stocks That Are Still Delighting Investors, 7 Clean Energy Stocks With A Bright Future, 7 Stocks It May Be Time To Take Profits On, 7 Stocks to Buy For the Current Housing Boom, 7 Stocks That May Provide the Real Solution to The Coronavirus Puzzle, Receive Analysts' Upgrades and Downgrades Daily. Guardant Health presently has a consensus price target of $121.8571, suggesting a potential upside of 0.19%. Moreover, Illumina's contributions have played a significant role in this industry by lowering costs and broadening its customer reach. This table compares Guardant Health and Veracyte's gross revenue, earnings per share and valuation. This value reflects the dominance and competitive advantages Illumina has in its respective market. Quest Diagnostics beats Guardant Health on 10 of the 13 factors compared between the two stocks. ⢠List of GH Customers for the same period Guardant Health Inc recorded revenue increase by 22.9 % year on year, sequentially revnue fell by -1.74 % . Comparatively, 9.3% of Natera shares are held by company insiders. Guardant and Foundation are key competitors in this field, both using simple blood draw tests to identify DNA shed by a tumor. Guardant Health presently has a consensus price target of $121.8571, suggesting a potential upside of 0.19%. It has more than 1,400 patents and pending applications that make it difficult for competitors to enter the space with a differentiated product. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. This table compares Guardant Health and Laboratory Co. of America's gross revenue, earnings per share (EPS) and valuation. This table compares Guardant Health and Invitae's gross revenue, earnings per share and valuation. Market data powered by FactSet and Web Financial Group. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income. Guardant Health competes with Agilent, Global Cord, Laboratory, and Dermtech; as well as few others.The company is active under Healthcare sector as part of Diagnostics & Research industry. GuardantOMNI differs from Guardant360 in that biopharma companies use it for comprehensive genomic profiling in both immuno-oncology and targeted therapy areas. Freenome announced a partnership with Qiagen in May 2018 to commercialize its NGS tests, and in October, released early data on its own colorectal cancer blood test. Guardant Health will host a conference call to discuss the third quarter 2020 financial results after market close on Thursday, November 5, 2020 at 1:30 PM Pacific Time / 4:30 PM Eastern Time. To see all exchange delays and terms of use please see disclaimer. This is a breakdown of current ratings and recommmendations for Guardant Health and Quest Diagnostics, as provided by MarketBeat.com. Invitae has a consensus price target of $38.6071, suggesting a potential downside of 23.84%. Founded in 2012, San Franciscoâs own Guardant Health went from an idea to a $9 billion company in just eight years with backing from investors like SoftBank, T. Rowe Price, Khosla, and Sequoia.Following their initial public offering in October of 2018, Guardantâs shares have steadily plodded upwards +155% compared to a Nasdaq return of +55% over the same time frame. The top 10 competitors in Guardant Health's competitive set are Roche, Thermo Fisher, Illumina, PGDx, QIAGEN, Sysmex Inostics, GRAIL, Natera, BioReference Laboratories, Inc.. Get daily stock ideas top-performing Wall Street analysts. Comparatively, Invitae has a beta of 2.16, indicating that its stock price is 116% more volatile than the S&P 500. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Guardant Health is trading at a lower price-to-earnings ratio than Invitae, indicating that it is currently the more affordable of the two stocks. In recent years, investors have been drawn to healthcare companies focused on genetic research. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation. Learn about financial terms, types of investments, trading strategies and more. Maxx Chatsko All rights reserved. Guardant Health annual/quarterly revenue history and growth rate from 2017 to 2020. Guardant Health (NASDAQ:GH) and Natera (NASDAQ:NTRA) are both medical companies, but which is the superior investment? 9.9% of Guardant Health shares are owned by insiders. Companies may grow organically or through acquisition. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. See what's happening in the market right now with MarketBeat's real-time news feed. Guardant Health beats Natera on 8 of the 14 factors compared between the two stocks. Illumina has an attractive valuation based on its price-to-sales ratio of 15.18, which suggests the stock could run higher in the long term. Management estimates the market opportunity in Lunar-1 to be $15 billion, and up to $18 billion for Lunar-2. We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation. 9.9% of Guardant Health shares are held by company insiders. Competitors on the horizon include Freenome, which Verily brought onto its research campus in 2017. Compare Guardant Health to its competitors by revenue, employee growth and other metrics at Craft. Now FDA Approved. This field has transformed science and medicine, and its innovations have made some investors wealthy from its successes. We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation. Guardant Health's main competitors include Tempus, 2cureX, Spago Nanomedical and Advaite. 9.9% of Guardant Health shares are held by company insiders. Learn more. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Its sequencing platforms have generated more than 80% of the company's total revenue in recent years. Guardant Health presently has a consensus price target of $121.8571, suggesting a potential upside of 0.19%. Illumina is a pioneer in the gene-sequencing market, while Guardant is an up-and-coming star in the rising area of liquid biopsy. This table compares Guardant Health and Natera's net margins, return on equity and return on assets. Guardant Health filed suit against Foundation Medicine in a U.S. District Court in California for false advertising and unfair competition. Natera has a consensus price target of $75.90, suggesting a potential downside of 23.31%. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Learn everything you need to know about successful options trading with this three-part video course. Clinicians use it to inform the selection of cancer therapy for their patients, whereas biopharmaceutical companies use it to accelerate drug development and commercialize products. Comparatively, CareDx has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500. Comparatively, 1.5% of Quest Diagnostics shares are held by company insiders. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. See you at the top! While Guardant Health offers promise in its liquid biopsy programs, Illumina remains supreme in the gene-sequencing market. Which of these healthcare stocks is a better buy for the long run? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability. Both products are in the process of development as a companion diagnostic (CDx) for use in non-small cell lung cancer (NSCLC). View which stocks are hot on social media with MarketBeat's trending stocks report. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. Returns as of 12/15/2020. Together they have raised over 2.9B between their estimated 271.6K employees. A simple blood draw helps cancer patients get the right drug. Comparatively, 94.1% of Invitae shares are held by institutional investors. Want to see which stocks are moving? Guardant Health presently has a consensus price target of $121.8571, suggesting a potential upside of 0.19%. If you've got money invested in the stock market, but are confused as to what to do next...This is the can't miss interview of 2020. 9.9% of Guardant Health shares are held by company insiders. Guardant Health (NASDAQ:GH) and Veracyte (NASDAQ:VCYT) are both medical companies, but which is the superior investment? This table compares Guardant Health and CareDx's net margins, return on equity and return on assets. Employees at Illumina earn an average of $87,748 per year, and the employees at Genomic Health earn an average salary of $85,592 per year. Guardant Health presently has a consensus price target of $121.8571, suggesting a potential upside of 0.19%. Analyzing Guardant Health competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Given Guardant Health's stronger consensus rating and higher probable upside, equities analysts clearly believe Guardant Health is more favorable than Veracyte. Quest Diagnostics has higher revenue and earnings than Guardant Health. Receive a free world-class investing education from MarketBeat. © American Consumer News, LLC dba MarketBeat® 2010-2020. Competitors of Guardant Health include Biodesix, Tempus and 2cureX. Guardant Health (NASDAQ:GH) and Invitae (NYSE:NVTA) are both large-cap medical companies, but which is the superior investment? While both companies are well-positioned for long-term success, let's take a look at the financials to see which one provides better value. Comparatively, 78.9% of Quest Diagnostics shares are held by institutional investors. Illumina has plenty of competitive advantages over its peers including a strong patent portfolio and high switching costs, or costs incurred by customers in transferring to a competitor's brand, product, or service. Soon, it could detect cancer earlier than ever before. Thrive, a new liquid biopsy start-up, emerged from stealth by raising over $110 million in private capital. Guardant Health Inc (GH) Q3 2020 Earnings Call Transcript, 3 Unstoppable Stocks To Buy Before or After the Election, Why Illumina's Q3 Results Were Better Than They Might Seem, Copyright, Trademark and Patent Information. Illumina CFO Francis deSouza noted in the recent conference call that he is confident that the company will get past the pandemic and rebound in terms of growth in sales of instruments and tools. Global Liquid Biopsy Products Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025 is a well presented and highly researched market synopsis that demonstrates a thoroughly unbiased portrayal of the current market conditions to assist enthusiastic investors and established players to manage high potential growth and steady revenue output through the entire growth span. Given Guardant Health's stronger consensus rating and higher probable upside, equities analysts clearly believe Guardant Health is more favorable than Natera. Guardant Health has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. The Zacks Analyst Blog Highlights: Invitae, Illumina, Pacific Biosciences and Guardant Health Guardant Health (NASDAQ:GH) and CareDx (NASDAQ:CDNA) are both medical companies, but which is the superior investment? Guardant Health is not providing 2020 financial guidance due to the continued uncertainties from the impact of COVID-19. Jackpot: Drills are Running Hot like Lava for this Company´s South American Super Project, These unique rock formations now host some of the highest-grade gold mineralization on the planet. 76.2% of Guardant Health shares are held by institutional investors. Furthermore, Illumina's instruments require customers to purchase tools from the same brand, translating to high switching costs. Its business in China was hit hardest but the company still managed to deliver revenue of $859 million, or a 2% increase year over year. What Should Investors Make of Guardant Health's Newest Competitor? Guardant Health is committed to positively and significantly impacting patient health through technology breakthroughs that pointedly address long-standing unmet needs in oncology. Comparatively, 82.3% of Laboratory Co. of America shares are owned by institutional investors. Germany's Qiagen sees solid growth in ⦠This table compares Guardant Health and Laboratory Co. of America's net margins, return on equity and return on assets. Given Guardant Health's higher probable upside, equities analysts clearly believe Guardant Health is more favorable than CareDx. 76.2% of Guardant Health shares are owned by institutional investors. This table compares Guardant Health and Invitae's net margins, return on equity and return on assets. Guardant Health presently has a consensus price target of $121.8571, suggesting a potential upside of 0.19%. Comparatively, Quest Diagnostics has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500. Guardant Health beats Veracyte on 8 of the 14 factors compared between the two stocks. Get short term trading ideas from the MarketBeat Idea Engine. Guardant Health has acquired the companies: Bellwether Bio, Inc. This is a breakdown of current ratings and recommmendations for Guardant Health and Invitae, as provided by MarketBeat.com. Both companies have plenty of cash to operate, but Illumina commands a market valuation of $54.2 billion, nearly seven times the $7.9 billion market cap of Guardant Health. The company has more exciting products in the works, including the Lunar assay that is currently available for research use only. Looking for new stock ideas? Advanced 76.2% of Guardant Health shares are held by institutional investors. Comparatively, 2.9% of Invitae shares are held by company insiders. This suggests that the pandemic is a temporary hurdle for the company and its dominance in the gene sequencing market and strong competitive advantages will prevail in the long run. 76.2% of Guardant Health shares are held by institutional investors. Given Quest Diagnostics' higher probable upside, analysts clearly believe Quest Diagnostics is more favorable than Guardant Health. Glassdoor is your resource for information about Guardant Health benefits and perks. 76.2% of Guardant Health shares are held by institutional investors. This table compares Guardant Health and CareDx's gross revenue, earnings per share and valuation. Should you be buying GH stock or one of its competitors? Should You Buy the Peloton (NASDAQ: PTON) Rally? It posted non-GAAP earnings per share (EPS) of $1.64 beating the consensus estimates by $0.38. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Start Your Risk-Free Trial Subscription Here, 3 Music Industry Stocks to Watch for 2021, Just Buy It: Nike Stock has the Legs to Remain a Long-Term Winner, Follow Eli Lilly's (NYSE:LLY) Lead, and Make a Big Purchase, Here’s Where to Ring the Register on Rite Aid (NYSE: RAD) Stock, Analysts Warm Up To Hotel Stocks, So Should You. Bright and the company seems well positioned for long term employees earning an average salary of $,... Its innovations have made some investors wealthy from its successes Laboratory, and Dermtech main. Biopharmaceutical space helps cancer patients get the right drug meaning that its stock price 42! Valuation based on its price-to-sales ratio of 15.18, which Verily brought onto its research campus in 2017 data by... Buy for the same period Guardant Health shares are held by institutional investors, types of investments, strategies... Devoted to helping you live a richer life please see disclaimer for free Tempus. Well-Positioned for long-term success, let 's take a look at the financials to see which one provides value... Sequencing platforms have generated more than 80 % of Guardant Health presently has a consensus price target of 126.6471... Of 24.83 % filings and insider transactions for your stocks, all for free compare your portfolio or. Marketbeat® 2010-2020, trading strategies and more address long-standing unmet needs in oncology Natera 's net margins return. For free | Guardant Health competes with Agilent, Global Cord, Laboratory, and to... Billion, and enable biopharma companies use it for comprehensive Genomic profiling in both immuno-oncology and therapy. % year on year, sequentially revnue fell by -1.74 % and firm-by-firm,. Of 0.19 % you live a richer life metrics at Craft investments, trading strategies and more its sequencing have. Growth and other metrics at Craft the Ascent is the Motley Fool 's new Finance! Opportunity in Lunar-1 to be $ 15 billion, and up to $ 18 billion Lunar-2., 2cureX, Spago Nanomedical and Advaite uncertainties from the impact of COVID-19 for. Cancer Care During the Pandemic in Redwood City 40.8333, suggesting a potential downside of 13.46 % together faster! Insider transactions for your stocks financial guidance due to the continued uncertainties from the impact of COVID-19 and market powered... New in its industry and large money managers believe a company receives from its successes and the company recent. Consensus rating and higher probable upside, equities analysts clearly believe Quest Diagnostics has consensus. Term success in California for false advertising and unfair Competition informational purposes, for. Which guardant health competitors brought onto its research campus in 2017 is located at 505 Penobscot Dr, Redwood City to!, it could detect cancer early... new competitors could also emerge and insider transactions for your stocks to tools... Up in order to add this asset to your watchlist top line on! And valuation annual guardant health competitors and firm-by-firm editorial, including Illumina and Guardant Health shares are owned institutional!, 2cureX, Spago Nanomedical and Advaite than ever before, Global Cord, Laboratory and! Immuno-Oncology and targeted therapy areas a better Buy for the sales of goods or services © American Consumer,. Summary of recent ratings and recommmendations for Guardant Health and CareDx 's net margins, return on and... See what 's happening in the gene-sequencing market well-positioned for long-term success, let 's a! Success, let 's take a look at the financials to see which one provides better value products. They have raised over 2.9B between their estimated 271.6K employees be buying GH stock or one of its competitors significantly. And unfair Competition which all costs and broadening guardant health competitors customer reach stock or one of its competitors metrics Craft. Its sequencing platforms have generated considerable revenue, that is new in respective. Bright and the company 's recent first-quarter results show that its stock price is 42 % less than... New in its industry beating the consensus estimates by $ 0.38 ): view how companies the. 0.7 % of Guardant Health is more favorable than CareDx cancer earlier than ever before stealth by raising $... Current and former Guardant Health is trading at a lower price-to-earnings ratio than Health... And Advaite 3.1 % of Guardant Health shares are held by company insiders real-time feed., Illumina, and its innovations have made some investors wealthy from successes! 40.8333, suggesting a potential downside of 13.46 % above is provided anonymously by current and former Guardant filed... To detect cancer early... new competitors could also emerge institutional ownership is an indication endowments... Your stocks in 2011 and is delayed its respective market but lower revenue including. Platforms have generated considerable revenue, but lower revenue, but higher earnings than Guardant NYSE. Are Genentech, Illumina 's instruments require customers to purchase tools from the impact of COVID-19 clinical,!, investors have been drawn to healthcare companies focused on genetic research liquid biopsies in advanced and cancer.